Title:
HERCEPTIN(REGISTERED TRADEMARK) ADJUVANT THERAPY
Document Type and Number:
Japanese Patent JP2017132805
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide more effective medical care of subjects with nonmetastatic breast cancer.SOLUTION: The invention concerns the results obtained in clinical studies of the adjuvant use of HERCEPTIN(R) in human subjects with nonmetastatic, high-risk, breast cancer. The invention concerns a method of adjuvant therapy comprising administering to a human subject with nonmetastatic HER2 positive breast cancer, following radical surgery, an effective amount of an antibody which binds to HER2 Domain IV bound by trastuzumab (HERCEPTIN(R)) and at least one chemotherapeutic agent, so as to extend disease free survival (DFS) or overall survival (OS) in the subject, where the DFS or the OS is evaluated about 2 to 5 years after the initiation of the treatment.SELECTED DRAWING: None
Inventors:
BRYANT JOHN L
Application Number:
JP2017088351A
Publication Date:
August 03, 2017
Filing Date:
April 27, 2017
Export Citation:
Assignee:
GENENTECH INC
International Classes:
A61K39/395; A61K9/127; A61K31/337; A61K31/519; A61K31/704; A61K31/7048; A61K31/7068; A61K45/00; A61P15/00; A61P35/00; A61P43/00; G16H20/10
Other References:
"Herceptin Combined With Chemotherapy Improves Disease-Free Survival For Patients With Early-Stage B", SCIENCEDAILY, JPN7017004116, 27 April 2005 (2005-04-27)
特集 分子標的治療薬の臨床評価 ＴＲＡＳＴＵＺＵＭＡＢ（ＨＥＲＣＥＰＴＩＮ）: "佐伯俊昭 外1名", 癌と化学療法, vol. 30, no. 8, JPN6017047610, August 2003 (2003-08-01), JP, pages 1094 - 1099
特集 分子標的治療薬の臨床評価 ＴＲＡＳＴＵＺＵＭＡＢ（ＨＥＲＣＥＰＴＩＮ）: "佐伯俊昭 外1名", 癌と化学療法, vol. 30, no. 8, JPN6017047610, August 2003 (2003-08-01), JP, pages 1094 - 1099
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita